• Je něco špatně v tomto záznamu ?

Repeat Stereotactic Radiosurgery for Progressive or Recurrent Vestibular Schwannomas

C. Iorio-Morin, R. Liscak, V. Vladyka, H. Kano, RC. Jacobs, LD. Lunsford, O. Cohen-Inbar, J. Sheehan, R. Emad, KA. Karim, A. El-Shehaby, WA. Reda, CC. Lee, FY. Pai, A. Wolf, D. Kondziolka, I. Grills, KC. Lee, D. Mathieu,

. 2019 ; 85 (4) : 535-542. [pub] 20191001

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006786

BACKGROUND: Stereotactic radiosurgery (SRS) is a highly effective management approach for patients with vestibular schwannomas (VS), with 10-yr control rates up 98%. When it fails, however, few data are available to guide management. OBJECTIVE: To perform a retrospective analysis of patients who underwent 2 SRS procedures on the same VS to assess the safety and efficacy of this practice. METHODS: This study was opened to centers of the International Gamma Knife Research Foundation (IGKRF). Data collected included patient characteristics, clinical symptoms at the time of SRS, radiosurgery dosimetric data, imaging response, clinical evolution, and survival. Actuarial analyses of tumor responses were performed. RESULTS: Seventy-six patients from 8 IGKRF centers were identified. Median follow-up from the second SRS was 51.7 mo. Progression after the first SRS occurred at a median of 43 mo. Repeat SRS was performed using a median dose of 12 Gy. Actuarial tumor control rates at 2, 5, and 10 yr following the second SRS were 98.6%, 92.2%, and 92.2%, respectively. Useful hearing was present in 30%, 8%, and 5% of patients at first SRS, second SRS, and last follow-up, respectively. Seventy-five percent of patients reported stable or improved symptoms following the second SRS. Worsening of facial nerve function attributable to SRS occurred in 7% of cases. There were no reports of radionecrosis, radiation-associated edema requiring corticosteroids, radiation-related neoplasia, or death attributable to the repeat SRS procedure. CONCLUSION: Patients with progressing VS after radiosurgery can be safely and effectively managed using a second SRS procedure.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006786
003      
CZ-PrNML
005      
20200518133013.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/neuros/nyy416 $2 doi
035    __
$a (PubMed)30189018
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Iorio-Morin, Christian $u Division of Neurosurgery, Université de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, Québec, Canada.
245    10
$a Repeat Stereotactic Radiosurgery for Progressive or Recurrent Vestibular Schwannomas / $c C. Iorio-Morin, R. Liscak, V. Vladyka, H. Kano, RC. Jacobs, LD. Lunsford, O. Cohen-Inbar, J. Sheehan, R. Emad, KA. Karim, A. El-Shehaby, WA. Reda, CC. Lee, FY. Pai, A. Wolf, D. Kondziolka, I. Grills, KC. Lee, D. Mathieu,
520    9_
$a BACKGROUND: Stereotactic radiosurgery (SRS) is a highly effective management approach for patients with vestibular schwannomas (VS), with 10-yr control rates up 98%. When it fails, however, few data are available to guide management. OBJECTIVE: To perform a retrospective analysis of patients who underwent 2 SRS procedures on the same VS to assess the safety and efficacy of this practice. METHODS: This study was opened to centers of the International Gamma Knife Research Foundation (IGKRF). Data collected included patient characteristics, clinical symptoms at the time of SRS, radiosurgery dosimetric data, imaging response, clinical evolution, and survival. Actuarial analyses of tumor responses were performed. RESULTS: Seventy-six patients from 8 IGKRF centers were identified. Median follow-up from the second SRS was 51.7 mo. Progression after the first SRS occurred at a median of 43 mo. Repeat SRS was performed using a median dose of 12 Gy. Actuarial tumor control rates at 2, 5, and 10 yr following the second SRS were 98.6%, 92.2%, and 92.2%, respectively. Useful hearing was present in 30%, 8%, and 5% of patients at first SRS, second SRS, and last follow-up, respectively. Seventy-five percent of patients reported stable or improved symptoms following the second SRS. Worsening of facial nerve function attributable to SRS occurred in 7% of cases. There were no reports of radionecrosis, radiation-associated edema requiring corticosteroids, radiation-related neoplasia, or death attributable to the repeat SRS procedure. CONCLUSION: Patients with progressing VS after radiosurgery can be safely and effectively managed using a second SRS procedure.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $x chirurgie $7 D009364
650    _2
$a vestibulární schwannom $x chirurgie $7 D009464
650    _2
$a radiochirurgie $x metody $7 D016634
650    12
$a reoperace $7 D012086
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Liscak, Roman $u Na Homolce Hospital, Prague, Czech Republic.
700    1_
$a Vladyka, Vilibald $u Na Homolce Hospital, Prague, Czech Republic.
700    1_
$a Kano, Hideyuki $u Department of Neurological Surgery, Center for Image-Guided Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
700    1_
$a Jacobs, Rachel C $u Department of Neurological Surgery, Center for Image-Guided Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
700    1_
$a Lunsford, L Dade $u Department of Neurological Surgery, Center for Image-Guided Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
700    1_
$a Cohen-Inbar, Or $u Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia.
700    1_
$a Sheehan, Jason $u Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia.
700    1_
$a Emad, Reem $u National Cancer Institute, Cairo University, Gamma Knife Center Cairo, Cairo, Egypt.
700    1_
$a Karim, Khalid Abdel $u Clinical Oncology Department, Ain Shams University, Gamma Knife Center Cairo, Cairo, Egypt.
700    1_
$a El-Shehaby, Amr $u Neurosurgery Department, Ain Shams University, Gamma Knife Center Cairo, Cairo, Egypt.
700    1_
$a Reda, Wael A $u Neurosurgery Department, Ain Shams University, Gamma Knife Center Cairo, Cairo, Egypt.
700    1_
$a Lee, Cheng-Chia $u Taipei Veterans General Hospital Neurological Institute, Taipei, Taiwan.
700    1_
$a Pai, Fu-Yuan $u Taipei Veterans General Hospital Neurological Institute, Taipei, Taiwan.
700    1_
$a Wolf, Amparo $u New York University Langone Medical Center, New York, New York.
700    1_
$a Kondziolka, Douglas $u New York University Langone Medical Center, New York, New York.
700    1_
$a Grills, Inga $u Beaumont Gamma Knife Center, Royal Oak, Michigan.
700    1_
$a Lee, Kuei C $u Beaumont Gamma Knife Center, Royal Oak, Michigan.
700    1_
$a Mathieu, David $u Division of Neurosurgery, Université de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, Québec, Canada.
773    0_
$w MED00003511 $t Neurosurgery $x 1524-4040 $g Roč. 85, č. 4 (2019), s. 535-542
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30189018 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200518133013 $b ABA008
999    __
$a ok $b bmc $g 1525644 $s 1096842
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 85 $c 4 $d 535-542 $e 20191001 $i 1524-4040 $m Neurosurgery $n Neurosurgery $x MED00003511
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace